Management of idiopathic membranous nephropathy

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 13, 2010, Pages 2163-2175

  Ponticelli, Claudio ^a   Passerini, Patrizia ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Glomerulonephritis; Immunosuppressive therapy; Membranous nephropathy; Nephrotic syndrome

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCINEURIN INHIBITOR; CHLORAMBUCIL; CORTICOTROPIN; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ECULIZUMAB; GLUCOCORTICOID; HYDROCHLOROTHIAZIDE; IMMUNOGLOBULIN; LISINOPRIL; LOOP DIURETIC AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; RITUXIMAB; STATIN; TACROLIMUS; WARFARIN;

ANTICOAGULATION; CARDIOVASCULAR RISK; CELL GROWTH; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MEGADOSE; DRUG WITHDRAWAL; EDEMA; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; IDIOPATHIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY VEIN THROMBOSIS; LOW DRUG DOSE; LUNG EMBOLISM; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PROTEINURIA; REMISSION; REVIEW; THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; MALE; NEPHROTIC SYNDROME; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77955816666     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.494599     Document Type: Review

References (89)

1. Debiec H, Guigonis V, Mougenot B, et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 2002;346:2053-2060
2. Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361:11-21
3. Prunotto M, Carnevali ML, Candiano G, et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 2010;21:507-519
4. Ponticelli C. Membranous nephropathy. J Nephrol 2007;20:268-287
5. Cattran DC. Idiopathic membranous nephropathy. Kidney Int 2001;59:1983-1994
6. Blainey JD, Brewer DB, Hardwicke J. Proteinuric glomerular disease in adults: cumulative life tables over twenty years. Q J Med 1986;59:557-567
7. Donadio JV Jr, Torres VE, Velosa JA, et al. Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int 1988;33:708-715
8. Noel LH, Zanetti M, Droz D, et al. Long-term prognosis of idiopathic membranous glomerulonephritis. Study of 116 untreated patients. Am J Med 1979;66:82-90
9. Troyanov S, Roasio L, Pandes M, et al. Renal pathology in idiopathic membranous nephropathy: a new perspective. Kidney Int 2006;69:1641-1648
10. Cattran DC, Pei Y, Greenwood CM, et al. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 1997;51:901-907
11. Chiurchiu C, Remuzzi G, Ruggenenti P. Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses. J Am Soc Nephrol 2005;16(Suppl 1):S58-63
12. Benigni A, Tomasoni S, Gagliardini E, et al. Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J Am Soc Nephrol 2001;12:941-948
13. Praga M, Borstein B, Andres A. Nephrotic proteinuria without hypoalbuminemia: clinical characteristics and response to angiotensin-converting enzyme inhibition. Am J Kidney Dis 1991;17:330-338
14. Ambalavanan S, Fauvel JP, Sibley RK, Myers BD. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. J Am Soc Nephrol 1996;7:290-298
15. Stegeman CA, De Zeeuw D, de Jong PE. Treatment of idiopathic membranous nephropathy: the dilemma of who, when, and how. Nephrol Dial Transplant 1995;10:1982-1984
16. Bellomo R, Atkins RC. Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted? Nephron 1993;6:249-254
17. Sarasin FP, Schifferli JA. Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int 1994;45:578-585
18. Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol 2007;18:2221-2225
19. Hladunewich MA, Troyanov S, Calafati J, et al. The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol 2009;4:1417-1422
20. Ponticelli C, Passerini P, Altieri P, et al. Remissions and relapses in idiopathic membranous nephropathy. Nephrol Dial Transplant 1992;7(Suppl 1):85-90
21. Troyanov S, Wall CA, Miller JA, et al. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 2004;66:1199-1220
22. Polanco N, Gutiérrez E, Covars?́ A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010;21:697-704
23. Cattran DC, Reich HN, Beanlands HJ, et al. The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant 2008;23:2247-2253
24. Ponticelli C. Glucocorticoids and immunomodulating agents in treatment of primary glomerulonephritis. In: Ponticelli C, Glassock RJ, editors, Oxford University Press, Oxford; 2009. p. 47-127
25. Hopper J Jr, Trew PA, Biava CG. Membranous nephropathy: its relative benignity in women. Nephron 1981;29:18-24
26. Shiiki H, Saito T, Nishitani Y, et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int 2004;65:1400-1407
27. Black DAK, Rose G, Brewer DB. Controlled trial of prednisone in adult patients with nephrotic syndrome. Br Med J 1970;3:421-426
28. Cattran DC, Delmore T, Roscoe J, et al. A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med 1989;320:8-13
29. Cameron JS, Healy MJ, Adu D. The medical research council trial of short-term high-dose alternate-day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. Q J Med 1990;274:133-156
30. Collaborative study of the adult idiopathic nephrotic syndrome: a controlled study of short-term prednisone treatment in adults with membranous nephropathy. N Engl J Med 1979;301:1301-1306
31. Hogan SL, Muller KE, Jennette JC, et al. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis 1995;25:862-875
32. Lagrue G, Bernard D, Bariety J, et al. Traitement par le chlorambucil et lazathioprine dans les glomerulonephrites primitives: resultats dune etude controllée. J Urol Nephrol 1975;81:655-672
33. Murphy BF, McDonald I, Fairley KF, Kincaid-Smith PS. Randomized controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous glomerulonephritis. Clin Nephrol 1992;37:229-234
34. Donadio JV Jr, Torres VE, Velosa JA, et al. Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int 1988;33:708-715
35. du Buf-Vereijken PW, Branten AJ, Wetzels JF, Membranous Nephropathy Study Group. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. Nephrol Dial Transplant 2004;19:1142-1148
36. Hofstra JM, Branten AJ, Wirtz JJ, et al. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial. Nephrol Dial Transplant 2010;25:129-136
37. Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegeners granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008;35:100-105
38. Jacob HS. Pulse steroids in haematological diseases. Hosp Pract 1985;8:87-94
39. Weil JM, Packard BG. Methylprednisolone inhibits the alternative and amplification pathways of complement. Infect Immun 1982;38:122-126
40. Ponticelli C, Zucchelli P, Imbasciati E, et al. Methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1984;310:946-950
41. Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995;48:1600-1604
42. Ponticelli C, Zucchelli P, Passerini P, et al. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. N Engl J Med 1992;327:599-603
43. Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998;9:444-450
44. Passerini P, Ponticelli C. Corticosteroids, cyclophosphamide, and chlorambucil therapy of membranous nephropathy. Semin Nephrol 2003;23:355-361
45. Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007;18:1899-1904
46. Berg AL, Arnadottir M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrol Dial Transplant 2004;19:1305-1307
47. Picardi L, Villa G, Galli F, et al. ACTH therapy in nephrotic syndrome induced by idiopathic membranous nephropathy. Clin Nephrol 2004;62:403-404
48. Ponticelli C, Passerini P, Salvadori M, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 2006;47:233-240
49. Arnadottir M, Stefansson B, Berg AL. A randomized study on treatment with adrenocorticotrophic hormone in idiopathic membranous nephropathy. J Am Soc Nephrol 2006;17:571A
50. Rauen T, Michaelis A, Floege J, Mertens PR. Case series of idiopathic membranous nephropathy with long-term beneficial effects of ACTH peptide 1-24. Clin Nephrol 2009;71:637-642
51. Ghiggeri GM, Bruschi M, Candiano G, et al. Depletion of clusterin in renal diseases causing nephritic syndrome. Kidney Int 2002;62:2184-2194
52. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002;2:725-734
53. Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008;14:931-938
54. Ponticelli C, Villa M. Does cyclosporine have a role in treatment of membranous nephropathy? Nephrol Dial Transplant 1999;14:23-25
55. Alexopoulos E, Pagianni A, Tsamelashvili M, et al. Induction and long-term treatment of membranous nephropathy with nephrotic syndrome. Nephrol Dial Transplant 2006;21:3127-3132
56. Ransom RF, Lam NG, Hallett MA, et al. Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization. Kidney Int 2005;68:2473-2483
57. Fritsche L, Budde K, Farber L, et al. Treatment of membranous glomerulopathy with cyclosporin A: how much patience is required? Nephrol Dial Transplant 1999;14:1036-1038
58. Cattran DC, Appel GB, Hebert LA, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001;59:1484-1490
59. Cattran DC, Alexopoulos E, Heering P, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int 2007;72:1429-1434
60. Praga M, Barrio V, Juarez GF, et al. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int 2007;71:924-930
61. Nangaku M, Pippin J, Richardson CA, et al. Beneficial effects of systemic immunoglobulin in experimental membranous nephropathy. Kidney Int 1996;50:2054-2062 (Pubitemid 26417550)
62. Yokoyama H, Goshima S, Wada T, et al. The short and long-term outcomes of membranous nephropathy treated with intravenous immune globulin therapy. Nephrol Dial Transplant 1999;14:2379-2386
63. Allison AC, Eugui EM, Sollinger HW. Micophenolate mofetil: mechanism of action and effects in transplantation. Transplant Rev 1993;7:129-139
64. Branten AJ, du Buf-Vereijken PW, Vervloet M, et al. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 2007;50:248-256
65. Dussol B, Morange S, Burtey S, et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis 2008;52:699-705
66. Chan TM, Lin AW, Tang SC, et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology (Carlton) 2007;12:576-581
67. Senthil Nayagam L, Ganguli A, Rathi M, et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transplant 2008;23:1926-1930
68. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2007;2:932-937
69. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359-7368
70. Waldman M, Appel GB. Update on the treatment of lupus nephritis. Kidney Int 2006;70:1403-1412
71. Remuzzi G, Chiurchiu C, Abbate M, et al. Rituximab for idiopathic membranous nephropathy. Lancet 2002;360:923-924
72. Ruggenenti P, Chiurchiu C, Abbate M, et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol 2006;1:738-748
73. Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008;73:117-125
74. Segarra A, Praga M, Ramos N, et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol 2009;4:1083-1088
75. Bomback AS, Derebail VK, McGregor JG, et al. Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol 2009;4:734-44, 117
76. Appel G, Nachman P, Hogan S, et al. Eculizumab (C5 complement inhibitor) in the treatment of idiopathic membranous nephropathy. J Am Soc Nephrol 2002;13:A68
77. Mathieson PW, Turner AN, Maidment CG, et al. Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function. Lancet 1988;2:869-872
78. Warwick GL, Geddes CG, Boulton-Jones JM. Prednisolone and chlorambucil therapy for idiopathic membranous nephropathy with progressive renal failure. Q J Med 1994;87:223-229
79. Brunkhorst R, Wrenger E, Koch KM. Low-dose prednisolone/chlorambucil therapy in patients with severe membranous glomerulonephritis. Clin Invest 1994;72:277-280
80. Reichert CJ, Koene KA, Wetzels JF, et al. Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide. Ann Intern Med 1994;121:328-333
81. Torres A, Dominguez-Gil B, Carreno A, et al. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int 2002;61:219-227
82. Glassock RJ. The treatment of idiopathic membranous nephropathy: a dilemma or a conundrum? Am J Kidney Dis 2004;44:562-566
83. Passerini P, Como G, Vigano E, et al. Idiopathic membranous nephropathy in the elderly. Nephrol Dial Transplant 1993;8:1321-1325
84. Rollino C, Basolo B, Roccatello D, et al. Outcome of membranous glomerulonephritis in the elderly. Contrib Nephrol 1993;105:71-74
85. Deegens JK, Wetzels JF. Membranous nephropathy in the older adults: epidemiology, diagnosis and management. Drugs Aging 2007;24:717-732
86. Ponticelli C. Cyclosporine: from renal transplantation to autoimmune diseases. Ann NY Acad Sci 2005;1051:551-558
87. Iijima K, Hamahira K, Tanaka R, et al. Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int 2002;61:1801-1805
88. Ruggenenti P, Perna A, Mosconi L, et al. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int 1998;53:1209-1216
89. Fervenza FC. Overcoming calcineurin dependence in membranous nephropathy: is rituximab the answer? Clin J Am Soc Nephrol 2009;4:1017-1019